DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - Specialty & Generic

Yuhan Corporation

000100KRX₩75,100+₩400 (+0.54%)Market closed

Price Chart

Daily

Key facts

Market Cap
₩5.53T
P/E
28.9x
P/B
2.43x
ROE
8.8%

Yuhan Corporation

Healthcare · Drug Manufacturers - Specialty & Generic · FY 2025

Yuhan Corporation is a prominent entity in the pharmaceutical industry, dedicated to the research, development, and distribution of a wide range of medical products and services. Headquartered in South Korea, Yuhan Corporation is involved in manufacturing prescription drugs, over-the-counter medications, and active pharmaceutical ingredients, supporting both domestic and international markets. In addition to pharmaceuticals, the company also explores biotechnological innovations and manufacturing partnerships to diversify its product offerings. Yuhan Corporation plays a critical role in improving public health by investing in cutting-edge research and fostering collaborations with global pharmaceutical leaders to bring innovative therapies to market. Its comprehensive portfolio addresses various medical needs, influencing sectors from general healthcare to specialized treatments. With a strong emphasis on corporate responsibility and sustainability, Yuhan Corporation prioritizes ethical business practices and environmental stewardship, contributing to its stature as a leading name in the pharmaceutical landscape.

CEO
조욱제
Employees
2,038

Company Statistics

Valuation

P/E
28.9x
P/B
2.43x
P/S
2.56x
EV/EBITDA
18.0x
P/FCF
−145.6x

Margins

Gross
33.4%
EBITDA
14.4%
Operating
4.8%
Pre-Tax
10.2%
Net
8.5%

Returns

ROA
6.0%
ROE
8.8%
ROIC
7.7%

Growth (CAGR)

Rev 3Yr
7.2%
Rev 5Yr
6.2%
Op Inc 3Yr
42.6%
Net Inc 3Yr
26.9%

Financial Health

Cash & Cash Equivalents
₩348.56B
Net Debt
₩510.08B
Debt/Equity
36.3%
Interest Cov
—

Profile

Revenue
₩2.19T
Shares Out
73.6M
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Yuhan Corporation (000100) Stock Forecast 2026 ₩75,100 — Price, Financials & Analyst Targets | AlphaLenz